Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers
Rattachement africain : cn, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Predictive biomarkers are urgently needed for first-line immune checkpoint inhibitors plus chemotherapy (ICI-chemo) in advanced non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) reflects tumor burden and immunogenicity, potentially identifyinging of patients suitable for ICI-chemo. In this study, pre- and on - treatment tissue and plasma samples are prospectively collected and analyzed from the randomized phase III CHOICE-01 trial comparing ICI - chemo versus chemotherapy alone in advanced NSCLC. Pre-treatment tissue and plasma samples, as well as on-treatment plasma samples, are prospectively collected. Tumor-informed ctDNA detection is based on tissue-identified mutations. Among patients with tumor-informed ctDNA positivity, those receiving ICI-chemo experienced significantly improved-free survival (PFS) and overall survival (OS) compared to those receiving chemotherapy alone (PFS: HR 0.45, 95% CI 0.34-0.60; OS: HR 0.66, 95% CI 0.49-0.88; p = 0.0045). In contrast, no significant differences in PFS or OS are observed between treatment arms in the ctDNA-negative subgroup. The predictive value of tumor-informed ctDNA is independent of other immune biomarkers and superior to other ctDNA metrics. Validation in a combined cohort from RATIONALE 304/307 trials shows similar results. Furthermore, ctDNA clearance during treatment correlates with better clinical outcomes (log-rank p = 0.0004 for OS and p = 0.044 for PFS).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers
- Date Crossref
- 25/11/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Chinese Academy of Medical Sciences & Peking Union Medical College pays non établi dans la noticeUniversité ou école supérieure
-
National Cancer Center pays non établi dans la noticeOrganisation à but non lucratif
-
Shanxi Provincial Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
Cancer Hospital of Chinese Academy of Medical Sciences pays non établi dans la noticeÉtablissement de santé
-
Burning Rock Biotech (China) pays non établi dans la noticeEntreprise
-
Chinese Academy of Medical Sciences and Peking Union Medical College State Key Laboratory of Molecular Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Department of Respiratory Medicine Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University ShanXi P. R. China Department of Respiratory Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Burning Rock Biotech Guangdong P. R. China Burning Rock Biotech pays non établi dans la noticeOrganisation à but non lucratif
Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center et Shanxi Provincial Cancer Hospital, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.